Pernix Therapeutics Holdings (PTX) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Join SI Premium – FREE
Pernix Therapeutics Holdings (NYSE: PTX) reported Q3 EPS of $0.08, $0.03 better than the analyst estimate of $0.05. Revenue for the quarter came in at $17.1 million versus the consensus estimate of $11.81 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
- Jack Henry (JKHY) Tops Q4 EPS by 13c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
